Charles Schwab’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-20,000
| Closed | -$80.8K | – | 3505 |
|
|
2025
Q1 | $80.8K | Hold |
20,000
| – | – | ﹤0.01% | 3365 |
|
|
2024
Q4 | $64K | Buy |
+20,000
| New | +$67.8K | ﹤0.01% | 3429 |
|
|
2022
Q4 | – | Sell |
-3,371
| Closed | -$36K | – | 3549 |
|
|
2022
Q3 | $36K | Hold |
3,371
| – | – | ﹤0.01% | 3401 |
|
|
2022
Q2 | $35K | Hold |
3,371
| – | – | ﹤0.01% | 3443 |
|
|
2022
Q1 | $60K | Hold |
3,371
| – | – | ﹤0.01% | 3505 |
|
|
2021
Q4 | $105K | Hold |
3,371
| – | – | ﹤0.01% | 3434 |
|
|
2021
Q3 | $112K | Buy |
3,371
+1,677
| +99% | +$49.6K | ﹤0.01% | 3369 |
|
|
2021
Q2 | $50K | Sell |
1,694
-10,796
| -86% | -$299K | ﹤0.01% | 3368 |
|
|
2021
Q1 | $393K | Sell |
12,490
-1,277
| -9% | -$42.8K | ﹤0.01% | 3164 |
|
|
2020
Q4 | $365K | Buy |
13,767
+1,402
| +11% | +$35.5K | ﹤0.01% | 3093 |
|
|
2020
Q3 | $332K | Buy |
12,365
+587
| +5% | +$14.1K | ﹤0.01% | 3001 |
|
|
2020
Q2 | $234K | Buy |
11,778
+4,257
| +57% | +$77.6K | ﹤0.01% | 3137 |
|
|
2020
Q1 | $114K | Buy |
7,521
+2,724
| +57% | +$48.2K | ﹤0.01% | 3096 |
|
|
2019
Q4 | $83K | Hold |
4,797
| – | – | ﹤0.01% | 3106 |
|
|
2019
Q3 | $120K | Hold |
4,797
| – | – | ﹤0.01% | 3085 |
|
|
2019
Q2 | $146K | Buy |
4,797
+3,139
| +189% | +$123K | ﹤0.01% | 3109 |
|
|
2019
Q1 | $48K | Buy |
+1,658
| New | +$52.9K | ﹤0.01% | 3134 |
|
Charles Schwab's CKPT Position: Q2 2025 in Review
Charles Schwab sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 20,000 shares — an estimated $80.8K sold.
Charles Schwab first reported a position in CKPT in Q1 2019 and held it in 17 quarters. The position peaked at $393K in Q1 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Charles Schwab reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Charles Schwab sold 20,000 Checkpoint Therapeutics shares in Q2 2025, an estimated $80.8K.
- Charles Schwab first reported a position in Checkpoint Therapeutics in Q1 2019 and held it in 17 quarters.
- Charles Schwab's Checkpoint Therapeutics position peaked at $393K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.